Treatment of Cancer Use Patent for EP4 antagonist Approved in US

On March 30, 2017 AskAt reported that it has received a notice of allowance dated March 30. 2017 from the United States Patent and Trademark Office (USPTO) in connection with the Application No. 14/547,247, a use patent of EP4 receptor antagonist for the treatment of Cancer (Press release, AskAt, MAR 30, 2017, View Source [SID1234535063]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!